These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 3403089)

  • 61. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
    McKellar PP
    Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Aztreonam: prevention of bacteremia in urologic surgery in patients with urinary infection].
    Dalet F; del Río G; Rabinad E
    Med Clin (Barc); 1988 Jan; 90(3):101-5. PubMed ID: 3352336
    [No Abstract]   [Full Text] [Related]  

  • 64. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
    Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Well-controlled comparative study on aztreonam and cefoperazone in the treatment of complicated urinary tract infections].
    Ohmori H; Kumon H; Kumamoto Y; Sakai S; Niijima T; Kishi H; Ohkoshi M; Kawamura N; Naide Y; Nishiura T
    Jpn J Antibiot; 1986 Jan; 39(1):24-56. PubMed ID: 3517407
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria.
    Cox CE
    Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment with aztreonam of gram negative infections in patients seropositive for HIV].
    Catania S; Mascellino MT; Trinchieri V; Musso R; Lorenzi A; Cirelli A
    Riv Eur Sci Med Farmacol; 1988 Aug; 10(4):317-21. PubMed ID: 3274906
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis.
    Dratwa M; Glupczynski Y; Lameire N; Matthys D; Verschraegen G; Vaneechoutte M; Boelaert J; Schurgers M; Van Landuyt H; Verbeelen D
    Rev Infect Dis; 1991; 13 Suppl 7():S645-7. PubMed ID: 2068475
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The use of aztreonam in serious gram-negative infections.
    Smith G; Bunney RG; Farrell ID; Wood MJ
    J Antimicrob Chemother; 1988 Feb; 21(2):233-41. PubMed ID: 3283094
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Aztreonam-flucloxacillin double beta-lactam treatment as empirical therapy of serious infections in very elderly patients.
    Knockaert DC; Dejaeger E; Nestor L; Verbist L; Pelemans W
    Age Ageing; 1991 Mar; 20(2):135-9. PubMed ID: 2053504
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aztreonam.
    Childs SJ; Bodey GP
    Pharmacotherapy; 1986; 6(4):138-52. PubMed ID: 3534798
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical experience with aztreonam in the treatment of gram-negative bacteremia.
    Scully BE; Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S789-93. PubMed ID: 3909338
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of aztreonam in the treatment of severe bacterial infections.
    Romero-Vivas J; Rodríguez-Créixems M; Bouza E; Hellín T; Guerrero A; Martínez-Beltrán J; García de la Torre M
    Antimicrob Agents Chemother; 1985 Aug; 28(2):222-6. PubMed ID: 3834832
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
    Swabb EA; Jenkins SA; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical efficacy of aztreonam in refractory infections in children].
    Ogura H; Hamada F; Fujieda M; Matsumoto K; Araki K; Ogura Y; Kuramitsu M; Kurashige T; Kitamura I
    Jpn J Antibiot; 1985 Nov; 38(11):3349-57. PubMed ID: 4094068
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections.
    Naber K; Kees F; Denk K; Bauernfeind A; Grobecker H
    Chemioterapia; 1987 Jun; 6(2 Suppl):517-8. PubMed ID: 3334613
    [No Abstract]   [Full Text] [Related]  

  • 80. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
    Simons WJ; Lee TJ
    Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.